180 Life Sciences: Leading Research into Solving one of the World’s Largest Drivers of Disease: Inflammation

    Dr. Jim Woody, CEO and Director of 180 Life Sciences, a clinical stage biotechnology company headquartered in Palo Alto, California, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis joins eHealth Radio and the <a href="https://ehealthradio.podbean.com/category/health-news" target="_blank" rel="noreferrer noopener">Health News Channel</a>.  Listen to interview with host <a href="https://www.linkedin.com/in/ericmdye/" target="_blank" rel="noreferrer noopener">Eric Michaels</a> and guest Dr. Jim Woody discuss the following: <ol><li>Please tell us a bit about your background, how 180 Life Sciences was founded and what the mission is behind the company.</li><li>The company's pipeline includes three families of novel drugs that address significant market opportunities in inflammation, fibrosis and pain. Can you share a brief overview of each?</li><li>What solutions has 180 Life Sciences developed within its anti-TNF program to address the pitfalls in current standards of care for diseases like fibrosis, POCD, or frozen shoulder?</li><li>How is 180 Life Sciences meeting the unmet need of patients suffering from inflammatory diseases differently than industry peers? </li><li>What can you share about the company's vision for safer pain management and the SCAs program?</li><li>Looking ahead, what exciting advances do you think are on the horizon for 180 Life Sciences?</li></ol>JAMES N. WOODY, M.D., Ph.D. is a Pediatric Immunologist that has managed many biotech companies, and invented both technologies and drugs that have been highly beneficial to patients. Dr. Woody has served as the CEO of <a href="https://180lifesciences.com" target="_blank" rel="noreferrer noopener">180 Life Sciences</a> since July 2020, and as a director of 180 since September 2020. Dr. Woody was a founder and served as Chairman of the Board of Directors for Viracta Pharmaceuticals, a lymphoma therapeutic company (July 2014 to December 2020). With the company undergoing a reverse merg